nach oben

Clinical Drug Investigation

Erschienen in:

01.08.2022 | Research Letter

Paxlovid-Tacrolimus Drug–Drug Interaction in a 23-Year-Old Female Kidney Transplant Patient with COVID-19

verfasst von: Noa Berar Yanay, Ido Bogner, Khader Saker, Elias Tannous

Erschienen in: Clinical Drug Investigation | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Excerpt

Kidney transplant patients are at a high risk for adverse severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection outcomes in terms of morbidity and mortality. Therefore, these patients are candidates for additional pharmacotherapy. Paxlovid was authorized as such a therapy in December 2021. Because of potential paxlovid drug–drug interactions, transplanted patients receiving calcineurin inhibitors must be monitored. We report on a case of a kidney transplant patient who received paxlovid for SARS-CoV-2 infection who developed a drug–drug interaction with tacrolimus. …

Nur mit Berechtigung zugänglich

Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics. Simple implementation and comparison with non-Bayesian methods. J Pharm Sci. 1982;71:1344–8.CrossRef

Størset E, Holford N, Hennig S, Bergmann TK, Bergan S, Bremer S, et al. Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. Br J Clin Pharmacol. 2014;78(3):509–23.CrossRef

Le Louedec F. mapbayr: MAP-Bayesian estimation of PK parameters. R package version 0.5.0. 2021. https://CRAN.Rproject.org/package=mapbayr. Accessed 6 Jul 2022.

Goffin E, Candellier A, Vart P, Noordzij M, Arnol M, Covic A, Lentini P, on behalf of ERACODA Collaborators. COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study. Nephrol Dial Transplant. 2021;36:2094–105. https://doi.org/10.1093/ndt/gfab200.CrossRefPubMedPubMedCentral

Quiroga B, Soler MJ, Ortiz A, Vaquera SM, Jarava Mantecon CJ, Useche G, et al. Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study. Nephrol Dial Transplant. 2021. https://doi.org/10.1093/ndt/gfab313.CrossRefPubMed

Caillard S, Chavarot N, Bertrand D, on behalf of the French Society of Transplantation. Occurrence of severe COVID-19 in vaccinated transplant patients. Kidney Int. 2021;100(2):477–9. https://doi.org/10.1016/j.kint.2021.05.011.CrossRefPubMedPubMedCentral

Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Weismandele W, for the EPIC-HR Investigators, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022. https://doi.org/10.1056/NEJMoa2118542.CrossRefPubMedPubMedCentral

National Institutes of Health. The COVID-19 treatment guidelines panel’s statement on therapies for elevated risk, nonhospitalized patients with mild to moderate COVID-19. January 19, 2022. https://www.covid19treatmentguidelines.nih.gov. Accessed 25 Jan 2022.

Fishbane S, Hirsch JS, Nair V. special considerations for paxlovid treatment among transplant recipients with SARS-COV-2 infection. Am J Kidney Dis. 2022. https://doi.org/10.1053/j.ajkd.2022.01.001.CrossRefPubMedPubMedCentral

Titel: Paxlovid-Tacrolimus Drug–Drug Interaction in a 23-Year-Old Female Kidney Transplant Patient with COVID-19
verfasst von: Noa Berar Yanay
Ido Bogner
Khader Saker
Elias Tannous
Publikationsdatum: 01.08.2022
Verlag: Springer International Publishing
Erschienen in: Clinical Drug Investigation / Ausgabe 8/2022
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI: https://doi.org/10.1007/s40261-022-01180-4

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Paxlovid-Tacrolimus Drug–Drug Interaction in a 23-Year-Old Female Kidney Transplant Patient with COVID-19

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2022

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy

Correction to: Foreword

Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet

Clinical Response to Futibatinib in Patients with High-Level FGFR2-Amplified Advanced Gastric Cancer: Two Case Reports

Modeling the Potential Impact of Remdesivir Treatment for Hospitalized Patients with COVID-19 in Saudi Arabia on Healthcare Resource Use and Direct Hospital Costs: A Hypothetical Study

Pharmacokinetic Drug–Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer